Lantheus (NASDAQ:LNTH) Posts Earnings Results, Beats Estimates By $0.21 EPS

Lantheus (NASDAQ:LNTH) announced its quarterly earnings data on Thursday. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21, FiscalAI reports. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter in the prior year, the company posted $1.53 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Lantheus updated its FY 2026 guidance to 5.000-5.250 EPS.

Here are the key takeaways from Lantheus’ conference call:

• FDA approved PYLARIFY TruVu (Mar 6); the new formulation enables larger batch sizes at high‑energy cyclotrons and will be transitioned site‑by‑site beginning in Q4 2026, with meaningful revenue expected in 2027 once HCPCS/TPT coding, payer readiness, and PMF approvals are in place.
• Q1 financials showed resilience — revenue of $377.3M (+1.2% YoY; +8.6% ex‑SPECT), strong operating cash flow ($125.1M) and free cash flow ($121.9M), PYLARIFY U.S. volume +5.8% YoY, and management reiterated 2026 guidance of $1.40–$1.45B revenue and $5.00–$5.25 adjusted EPS.
• NeuraCeq momentum — Q1 revenue $35.4M (14.3% q/q vs Q4 2025), positioning as the fastest‑growing beta‑amyloid agent with a growing PMF footprint (22 sites) to expand supply and deepen penetration amid DMT adoption and earlier diagnostic guidelines.
• PNT2003 received FDA tentative approval for GEP‑NETs (LUTATHERA equivalent), but final commercialization depends on the Hatch‑Waxman stay, related legal proceedings, and manufacturing/commercial readiness, and it is not materially included in 2026 guidance.
• Late‑stage pipeline catalysts — MK‑6240 (tau PET) has a PDUFA date of Aug 13, 2026 and is widely used in Alzheimer’s DMT trials; the company is prioritizing radiodiagnostics and selectively allocating capital while evaluating options for radiotherapeutic assets.

Lantheus Price Performance

Shares of LNTH traded up $2.06 during trading hours on Friday, hitting $93.06. The stock had a trading volume of 1,540,225 shares, compared to its average volume of 804,357. The company’s fifty day moving average is $79.69 and its two-hundred day moving average is $68.87. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.51. Lantheus has a 52 week low of $47.25 and a 52 week high of $94.86. The stock has a market capitalization of $6.06 billion, a price-to-earnings ratio of 22.42 and a beta of -0.08.

Key Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Lantheus reported first-quarter EPS of $1.46, beating estimates of $1.25, on revenue of $377.3 million, also above expectations. The beat suggests solid underlying demand and execution. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company issued FY2026 EPS guidance of $5.00 to $5.25, slightly above the consensus estimate, reinforcing expectations for continued profitability. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Citizens JMP raised its price target to $115 from $85 and reiterated a Market Outperform rating, implying meaningful upside from current levels. Tickerreport.com
• Positive Sentiment: Mizuho also lifted its price target to $100 from $95 and kept an Outperform rating, adding to the bullish post-earnings analyst momentum. Benzinga
• Neutral Sentiment: Several follow-up stories highlighted valuation and the earnings call transcript, but these were mainly commentary on the already-reported results rather than new catalysts. Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts

Institutional Investors Weigh In On Lantheus

Several large investors have recently made changes to their positions in LNTH. Smartleaf Asset Management LLC grew its holdings in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus in the 2nd quarter worth about $36,000. Parallel Advisors LLC grew its holdings in shares of Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Lantheus in the 4th quarter worth about $39,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Lantheus in the 3rd quarter worth about $55,000. Institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on LNTH shares. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Truist Financial increased their price objective on shares of Lantheus from $89.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, April 15th. Mizuho increased their price objective on shares of Lantheus from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $97.29.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.